Results 261 to 270 of about 4,953,128 (334)
In over 50% of non‐metastatic breast cancer patients, circulating tumor cells (CTCs) along the whole epithelial‐mesenchymal transition spectrum are detected. Total CTC number and individual phenotypes relate to aggressive disease characteristics, including lymph node involvement and higher tumor proliferation. At the single‐cell level, mesenchymal CTCs
Justyna Topa+14 more
wiley +1 more source
Conventional Cytogenetic Analysis of Solid Tumor Abnormalities: A 25-Year Review of Proficiency Test Results from the College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee. [PDF]
Vanderscheldon RK+14 more
europepmc +1 more source
The IFNγ‐CIITA‐MHC II axis modulates melanoma cell susceptibility to NK‐cell‐mediated cytotoxicity
Natural killer (NK) cells play a central role in anti‐melanoma immunity. However, melanoma cells adapt during co‐culture by upregulating CIITA and MHC II in response to interferon gamma (IFNγ), thereby evading NK‐cell lysis. Blocking IFNγ signaling or treatment with dimethyl fumarate/simvastatin counteracts this immune escape and maintains NK‐cell ...
Lena C. M. Krause+6 more
wiley +1 more source
Consideration of disease penetrance in the selection of secondary findings gene-disease pairs: A policy statement of the American College of Medical Genetics and Genomics (ACMG). [PDF]
Gordon AS+13 more
europepmc +1 more source
Gao et al. report that circular DNA molecules created as by‐products of V(D)J recombination during lymphocyte maturation (ESCs) can replicate and be retained for much longer than previously thought in healthy cells. In BCP‐ALL cells, increased ESC abundance correlates with a greater chance of relapse likely mediated by their ability to induce genome ...
Davide Pradella, Andrea Ventura
wiley +1 more source
Medical genetics in developing countries in the Asia-Pacific region: challenges and opportunities
M. Thong+3 more
semanticscholar +1 more source
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard+12 more
wiley +1 more source